Sangamo BioSciences | SGMO - Operating Profit


Sangamo BioSciences reported $-33.51M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
Alaunos Therapeutics USD -1.19M 432K Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
Amgen USD 3.96B 464M Dec/2025
Bayer EUR -543M 556M Sep/2025
BioCryst Pharmaceuticals USD -2.54M 10.23M Dec/2024
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -7.89M 540K Sep/2025
CSL USD 666M 1.31B Jun/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Grifols EUR 411.56M 15.51M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Omeros USD -35.41M 23.75M Sep/2024
Pfizer USD 4.65B 3.99B Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Tectonic Therapeutic USD -21.89M 440K Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025